Risk of infection in ocrelizumab-treated adults with multiple sclerosis aged 55 years and older: a retrospective cohort study. (PubMed, Lancet Reg Health Am) - Oct 7, 2026 - "Findings support individualized risk-benefit discussion, especially regarding UTIs in older patients of female sex, dedicated UTI monitoring and prevention protocols for older ocrelizumab-treated patients, and inclusion of this age group in future clinical trials. Investigator-initiated grant from Genentech."
Journal • Retrospective data • CNS Disorders • Infectious Disease • Multiple Sclerosis • Nephrology
|
|
Farrah J Mateen; Joseph Sadok; Justin Hill; Maya Mastick; Nomin Enkhtsetseg; Raphael Scheu; Seungwon Lee; Siddharth Satish
|